In a landmark corporate maneuver set to redefine its market standing, NexGel Inc. has announced its definitive agreement to acquire a cutting-edge regenerative biomaterial portfolio from Celularity, Inc. This strategic acquisition, hailed as the most significant milestone in NexGel's corporate trajectory, is poised to usher in an era of unprecedented growth and profitability for the medical technology firm. The transaction is not merely an expansion but a transformative step, promising to elevate NexGel's annual revenue to an impressive $35 million by 2026, effectively tripling its current earnings and establishing it as an immediate force in the competitive med-tech landscape.
Details of the Groundbreaking Acquisition and Future Outlook
On a pivotal Tuesday, March 10, 2026, NexGel Inc. formally entered into an agreement to license and acquire a robust suite of commercial-stage regenerative biomaterial products from Celularity, Inc., a distinguished entity in the realm of regenerative and cellular medicine. This acquired portfolio is a treasure trove of innovation, encompassing advanced products and technologies specifically engineered for tendon repair, pioneering skin grafts, and stimulating bone growth. These aren't nascent innovations; they boast over a decade of proven clinical application, underscoring their efficacy and the trust they've garnered within the medical community. Crucially, these products benefit from established insurance reimbursement pathways, ensuring a stable and predictable revenue stream for NexGel.
To facilitate this monumental acquisition and support its broader strategic objectives, NexGel is diligently working towards securing approximately $14.9 million in additional financing. This capital infusion, expected to materialize in the first quarter or early second quarter of 2026, comes on the heels of a previously announced financing round totaling $1.8 million. The combined financial backing is critical for solidifying the company's fiscal position as it integrates the new portfolio.
The strategic rationale behind this acquisition is multifaceted and compelling. NexGel anticipates that this deal will not only nearly triple its yearly revenue but also propel it into immediate profitability, significantly enhancing its stature within the medical technology industry. The integration of six commercial-stage regenerative biomaterial products, characterized by their proven clinical utility and sustained demand, is expected to provide an immediate boost to the company's financial health. Furthermore, NexGel has outlined plans for three additional 510(k) filings in 2026, 2027, and 2028, signaling a robust pipeline for sustained portfolio expansion and innovation. This synergistic combination is also expected to unlock new avenues for scaling complementary biomaterials and hydrogel technologies across diverse sectors, promising expanded sales opportunities. In a related development, NexGel's shares witnessed a positive movement, climbing 6.19% to $1.19 in premarket trading following the announcement, reflecting investor confidence in this transformative deal.
This acquisition marks a pivotal moment for NexGel, transforming it from a promising contender into a formidable leader in the regenerative medicine space. By integrating established products with a clear path to market and future innovation, NexGel is not just expanding its product line; it's investing in a future of sustained growth, enhanced profitability, and a more impactful presence in addressing critical healthcare needs.